BioVersys AG
BIOV
Company Profile
Business description
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The company focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others.
Contact
c/o Technologiepark
Hochbergerstrasse 60c
BaselCH-4057
CHET: +41 615515120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
29
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.50 | 11.40 | 0.12% |
| CAC 40 | 8,341.26 | 17.50 | -0.21% |
| DAX 40 | 25,430.74 | 25.40 | 0.10% |
| Dow JONES (US) | 49,295.51 | 294.69 | -0.59% |
| FTSE 100 | 10,113.44 | 27.26 | -0.27% |
| HKSE | 26,848.47 | 239.99 | 0.90% |
| NASDAQ | 23,737.25 | 3.35 | 0.01% |
| Nikkei 225 | 53,549.16 | 1,609.27 | 3.10% |
| NZX 50 Index | 13,656.05 | 27.24 | -0.20% |
| S&P 500 | 6,968.36 | 8.91 | -0.13% |
| S&P/ASX 200 | 8,808.50 | 17.20 | 0.20% |
| SSE Composite Index | 4,138.76 | 26.53 | -0.64% |